HOME >> BIOLOGY >> NEWS
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004

GlaxoSmithKline (GSK) is pleased to announce a call for applications for its 2004 Drug Discovery and Development Research Grant Program. GSK will award $250,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. Since the inception of the program in 2001, GSK has awarded $1.25 million and honored 14 researchers for their groundbreaking work toward new pharmaceutical strategies to combat the HIV virus.

Applications are now being solicited for 2004 research grants and must be submitted by July 31. For detailed information about the GSK Drug Discovery and Development Research Grant Program, as well as an application, please call 1-888-527-6935 or visit www.dddresearchgrant.com.

The one-time research grants range from $25,000 to $150,000 and are intended to further the development of inventive treatments for HIV/AIDS, including:

  • therapies aimed at treating infection,
  • prophylactic vaccines, or
  • microbicides designed to prevent transmission of the virus.

"As we enter the fourth year of the program, it's rewarding to witness the progress that the first grant recipients have made. The grants have enabled researchers to improve testing processes, submit research for publication, experiment with new hypotheses and strive to develop medications and vaccines for patients worldwide," said Doug Manion, M.D., vice president of clinical development and medical affairs for GSK. "We are pleased to help researchers in their quest to unlock the mysteries of HIV."

The research grant carries no obligation to the recipient's organization for licensure, patenting or transfer of confidential information, although GSK may discuss the possibility of future collaboration with some applicants.

An Expert Review Board composed of acknowledged leaders in the field of HIV/AIDS w
'"/>

Contact: Teresa Luepke
tluepke@pcipr.com
312-558-1770
Public Communications Inc.
30-Apr-2004


Page: 1 2 3

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. July 31 deadline approaching to apply for $500,000 in research grants from GlaxoSmithKline
3. Discovery of new shrimp species adds to unique family
4. Discovery of tiny microbes in ancient Greenland glacier may define limits for life on Earth
5. Discovery in parasite movement may offer insights into malaria
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Discovery helps explain how cells package DNA
8. Discovery offers clues to origin of life
9. Discovery could improve anemia treatment in patients
10. Discovery could lead to better treatment for cryptosporidum infections
11. Discovery of brain disorder gene paves way for genetic test

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... 2020 , ... BioFactura, Inc. today announced a $1 million ... & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). ... efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid ...
(Date:7/10/2020)... (PRWEB) , ... July 08, 2020 , ... ... on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 ... a comparability study, but what is the most effective way to complete one? ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global ... of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of ... located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a ... of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. ... lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine ...
Breaking Biology Technology:
Cached News: